Search research articles
Contact Us
Filters
Showing results (191-200 of 418) with videos related to
Page
of 42
Sort By:
Cancer Cell
|
July 7, 2007
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death
M Stacey Ricci, Seok-Hyun Kim, Kazuhiro Ogi, et al.
Journal for Immunotherapy of Cancer
|
June 21, 2022
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
Hussein A Tawbi, Caroline Robert, Jan C Brase, et al.
Melanoma Research
|
September 14, 2018
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma
Shalin Shah, Jason J Luke, Heather A Jacene, et al.
Nature Medicine
|
August 9, 2016
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma
Che-Hung Shen, Sun Hye Kim, Sebastian Trousil, et al.
Journal of Translational Medicine
|
September 30, 2024
Effect of the mRNA decapping enzyme scavenger (DCPS) inhibitor RG3039 on glioblastoma
Hao Duan, Yuan Xie, Suwen Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2015
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
Melissa A Wilson, Fengmin Zhao, Sanika Khare, et al.
BJU International
|
September 4, 2021
Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805
Jose A Karam, Maneka Puligandla, Keith T Flaherty, et al.
Cancer Discovery
|
March 18, 2016
Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
Miles A Miller, Madeleine J Oudin, Ryan J Sullivan, et al.
The Journal of Urology
|
October 10, 2019
Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial
Ziho Lee, Opeyemi A Jegede, Naomi B Haas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2017
Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805
Lucia B Jilaveanu, Maneka Puligandla, Sarah A Weiss, et al.
Page
of 42
Search research articles
Search
Showing results (191-200 of 418) with videos related to
Sort By:
Page
of 42
Cancer Cell
|
July 7, 2007
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death
M Stacey Ricci, Seok-Hyun Kim, Kazuhiro Ogi, et al.
Journal for Immunotherapy of Cancer
|
June 21, 2022
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
Hussein A Tawbi, Caroline Robert, Jan C Brase, et al.
Melanoma Research
|
September 14, 2018
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma
Shalin Shah, Jason J Luke, Heather A Jacene, et al.
Nature Medicine
|
August 9, 2016
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma
Che-Hung Shen, Sun Hye Kim, Sebastian Trousil, et al.
Journal of Translational Medicine
|
September 30, 2024
Effect of the mRNA decapping enzyme scavenger (DCPS) inhibitor RG3039 on glioblastoma
Hao Duan, Yuan Xie, Suwen Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2015
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
Melissa A Wilson, Fengmin Zhao, Sanika Khare, et al.
BJU International
|
September 4, 2021
Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805
Jose A Karam, Maneka Puligandla, Keith T Flaherty, et al.
Cancer Discovery
|
March 18, 2016
Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
Miles A Miller, Madeleine J Oudin, Ryan J Sullivan, et al.
The Journal of Urology
|
October 10, 2019
Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial
Ziho Lee, Opeyemi A Jegede, Naomi B Haas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2017
Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805
Lucia B Jilaveanu, Maneka Puligandla, Sarah A Weiss, et al.
Page
of 42